Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6560211 | 0.85 | KMT2A (0.70) | ROCK2ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL4522885 | 0.85 | ROCK2 (0.65) | ROCK2ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL4515679 | 0.83 | ROCK2 (0.79) | ROCK2ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL4517142 | 0.82 | ROCK2 (0.84) | ROCK2ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL4512176 | 0.82 | ROCK2 (0.77) | ROCK2ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL4523166 | 0.81 | ROCK2 (0.66) | ROCK2ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL14245445 | 0.81 | ROCK2 (0.60) | ROCK2ALDH1A1KMT2AMEN1PKM | |
| Hydrochloric Acid SCHEMBL4506859 | 0.81 | ROCK2 (0.75) | ROCK2ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL14246056 | 0.79 | ROCK2 (0.70) | ROCK2 | |
| SCHEMBL4515869 | 0.79 | ROCK2 (0.72) | ROCK2ALDH1A1ROCK1POLBABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | claimed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | claimed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | claimed |
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | ROCK2 32/4885ALDH1A1 2810/4885KMT2A 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.